INDEMNIFICATION AGREEMENTIndemnification Agreement • June 19th, 2006 • Sucampo Pharmaceuticals, Inc. • Delaware
Contract Type FiledJune 19th, 2006 Company JurisdictionINDEMNIFICATION AGREEMENT (this “Agreement”) dated as of May 26, 2004 by and between Sucampo Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Hidetoshi Mine (“Indemnitee”):
EMPLOYMENT AGREEMENTEmployment Agreement • June 19th, 2006 • Sucampo Pharmaceuticals, Inc.
Contract Type FiledJune 19th, 2006 CompanyTHIS EMPLOYMENT AGREEMENT (the “Agreement”), dated as of , 2006 (the “Effective Date”), is hereby entered into in the State of Maryland by and between SUCAMPO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and (“Executive”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • June 19th, 2006 • Sucampo Pharmaceuticals, Inc. • New York
Contract Type FiledJune 19th, 2006 Company JurisdictionTHIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made as of October 29, 2004, by and between Sucampo Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, having its principal place of business at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814 USA (“SPI”), and Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan, having its principal place of business at 1-1 Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”). SPI and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SUPPLY AND PURCHASE AGREEMENTSupply and Purchase Agreement • June 19th, 2006 • Sucampo Pharmaceuticals, Inc. • New York
Contract Type FiledJune 19th, 2006 Company JurisdictionTHIS SUPPLY AND PURCHASE AGREEMENT is made as of January 25, 2006, by and among Sucampo Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814 USA (“SPI”), Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (“Takeda”) and R-Tech Ueno, Ltd., a corporation organized under the laws of Japan having its principal place of business at 10F, Yamato Life Insurance Bldg., 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011, JAPAN (“RTU”) (this “Agreement”). SPI, Takeda and RTU are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. SUPPLY AGREEMENTSupply Agreement • June 19th, 2006 • Sucampo Pharmaceuticals, Inc. • New York
Contract Type FiledJune 19th, 2006 Company JurisdictionTHIS SUPPLY AGREEMENT is made as of October 29, 2004, by and among Sucampo Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814 USA (“SPI”), Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (“Takeda”) and R-Tech Ueno, Ltd., a corporation organized under the laws of Japan having its principal place of business at 10F, Yamato Life Insurance Bldg., 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011, JAPAN (“RTU”) (this “Agreement”). SPI, Takeda and RTU are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SUBLEASE AGREEMENTSublease Agreement • June 19th, 2006 • Sucampo Pharmaceuticals, Inc. • Maryland
Contract Type FiledJune 19th, 2006 Company JurisdictionTHIS SUBLEASE AGREEMENT (“Sublease”) is made this 26th day of October, 2005, by and between First Potomac Realty Investment L.P., a Delaware limited partnership (“Sublessor”) and Sucampo Pharmaceuticals, Inc., a Delaware corporation (“Sublessee”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. SUPPLEMENTAL AGREEMENTSupplemental Agreement • June 19th, 2006 • Sucampo Pharmaceuticals, Inc. • New York
Contract Type FiledJune 19th, 2006 Company JurisdictionTHIS SUPPLEMENTAL AGREEMENT (the “Supplemental Agreement”) is made as of February 1, 2006, by and between Sucampo Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, having its principal place of business at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814 USA (“SPI”), and Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan, having its principal place of business at 1-1 Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”). SPI and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
INDEMNIFICATION AGREEMENTIndemnification Agreement • June 19th, 2006 • Sucampo Pharmaceuticals, Inc. • Delaware
Contract Type FiledJune 19th, 2006 Company JurisdictionINDEMNIFICATION AGREEMENT (this “Agreement”) dated as of May 23, 2006 by and between Sucampo Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Gregory D. Perry (“Indemnitee”):
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. AGREEMENTConfidentiality Agreement • June 19th, 2006 • Sucampo Pharmaceuticals, Inc. • New York
Contract Type FiledJune 19th, 2006 Company JurisdictionTHIS AGREEMENT is made as of October 29, 2004, by and among Sucampo Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 4733 Bethesda Avenue, Suite 450, Bethesda, Maryland 20814 USA (“SPI”), Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (“Takeda”) and Sucampo AG, a corporation organized under the laws of Switzerland and having its principal office at Graben 5, CH-6300 Zug, Switzerland (“SAG”) (this “Agreement”). SPI, Takeda and SAG are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ARTICLE PAGE 1. DEFINITIONS 1 2. TERM 4 3. WORK AGREEMENT 4 4. RENT 5 5. ADDITIONAL RENT 6 6. USE 8 7. CARE OF PREMISES 8 8. ALTERATIONS BY TENANT 8 9. EQUIPMENT 9 10. OWNERSHIP AND REMOVAL OF PROPERTY 10 11. LANDLORD’S ACCESS TO PREMISES 11 12....Lease Agreement • June 19th, 2006 • Sucampo Pharmaceuticals, Inc. • Maryland
Contract Type FiledJune 19th, 2006 Company JurisdictionTHIS LEASE (the “Lease”) is made and entered into this 16th day of September, 1998, by and between TRIZECHAHN PLAZA WEST LIMITED PARTNERSHIP, a Maryland limited partnership (“Landlord”) and R-TECH UENO (USA), INC., a Delaware corporation (“Tenant”).